CD117、CD34和VEGF蛋白在子宫内膜增生向子宫内膜样癌进展过程中的表达
Expression of CD117, CD34, and VEGF proteins in progression from endometrial hyperplasia to endometrioid carcinoma.
作者信息
Hassan Wael Abdo, Ibrahim Rehab
机构信息
Department of Pathology, Faculty of Medicine, Suez Canal University Ismailia, Egypt.
Department of Basic Sciences, Sulaiman Al Rajhi University Al-Bukayriyah, KSA.
出版信息
Int J Clin Exp Pathol. 2020 Aug 1;13(8):2115-2122. eCollection 2020.
BACKGROUND
The risk of endometrial hyperplasia progressing into endometrioid carcinoma ranges from 1% for benign hyperplasia to 46.2% for endometrial intra-epithelial neoplasia. Differentiation between both types of hyperplasia is thus crucial for optimal management. The present study investigates the expression of the following immune-histochemical markers, for their potential roles in differentiating between both types of endometrial hyperplasia; as well as their expression in endometrial carcinoma: VEGF, CD34 and CD117.
METHODS
Tissue samples were obtained, fixed, processed, stained by hematoxylin and eosin for diagnosis, and then imunohistochemically stained using anti CD117, CD34, and VEGF antibodies.
RESULTS
In benign endometrial hyperplasia, the cells show weak expression to VEGF and CD34, and absent CD117. In endometrial intra-epithelial neoplasia, the cells show strong expression of VEGF and weak expression of CD34 and CD117. In case of endometrioid carcinoma, all cases showed strong reaction for VEGF and CD34, and moderate expression to CD117.
CONCLUSION
Our data suggests a role for CD117, CD34, and VEGF in progression from hyperplasia to carcinoma.
背景
子宫内膜增生进展为子宫内膜样癌的风险范围从良性增生的1%到子宫内膜上皮内瘤变的46.2%。因此，区分这两种增生类型对于优化治疗至关重要。本研究调查了以下免疫组化标志物的表达情况，以探讨它们在区分两种类型子宫内膜增生以及在子宫内膜癌中的潜在作用：血管内皮生长因子（VEGF）、CD34和CD117。
方法
获取组织样本，进行固定、处理，用苏木精和伊红染色以进行诊断，然后使用抗CD117、CD34和VEGF抗体进行免疫组化染色。
结果
在良性子宫内膜增生中，细胞对VEGF和CD34呈弱表达，CD117表达缺失。在子宫内膜上皮内瘤变中，细胞对VEGF呈强表达，对CD34和CD117呈弱表达。在子宫内膜样癌病例中，所有病例对VEGF和CD34均呈强反应，对CD117呈中度表达。
结论
我们的数据表明CD117、CD34和VEGF在从增生到癌的进展过程中发挥作用。
Zotero 插件